Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03373981 · ClinicalTrials.gov registry record · NA

Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS

A NA study, sponsored by Hospital for Special Surgery, New York.

Terminated
Registry status
NA
Development phase
3
Enrollment target

NCT03373981 is a NA study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03373981, a NA study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.

TERMINATED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

This is an open-label clinical trial to determine the safety of rTMS and efficacy in improving depression symptoms, quality of life and cognition deficits among patients with Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders.

Interventions

  • DEVICE rTMS

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2017-11-29
Est. Completion 2022-08-16
Phase NA

What the Registry Record Tells You About NCT03373981

The ClinicalTrials.gov registry entry for NCT03373981 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which rTMS is the first listed.

NCT03373981 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03373981 about?

NCT03373981 is a clinical study titled "Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS". This is an open-label clinical trial to determine the safety of rTMS and efficacy in improving depression symptoms, quality of life and cognition deficits among patients with Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders.

What is the current status of trial NCT03373981?

This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2017-11-29. Estimated completion is 2022-08-16.

What interventions are being tested in trial NCT03373981?

The interventions under investigation include: rTMS (DEVICE).

Who is sponsoring clinical trial NCT03373981?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.